Search

Search Constraints

You searched for: Subject Leukemia

Search Results

42. 13 THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL. (April 2015)

43. 130 REDUCED TOXICITY TREOSULFAN-BASED VS. REDUCED INTENSITY BUSULFAN-BASED CONDITIONING REGIMEN IN AML/MDS PATIENTS UNDERGOING ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A SINGLE CENTRE EXPERIENCE. Issue 1 (April 2015)

45. 132 RETROSPECTIVE ANALYSIS OF HIGH-RISK MYELODYSPLASTIC SYNDROME AND SECONDARY ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH ALLOGENEIC TRANSPLANTATION AT SAN RAFFAELE SCIENTIFIC INSTITUTE: A SINGLE CENTER EXPERIENCE. Issue 1 (April 2015)

46. 133 UNRELATED CORD BLOOD OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH MDS RECEIVING A REDUCED INTENSITY CONDITIONING REGIMEN: AN EBMT STUDY. Issue 1 (April 2015)

47. 134 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LOWER RISK MDS PATIENTS : A RETROSPECTIVE STUDY ON BEHALF OF THE CMWP OF THE EBMT. (April 2015)

48. 135 IN VITRO AZACITIDINE CULTURE INDUCES DNA DEMETHYLATION AND INCREASED MRNA-LEVELS IN PRIMARY MDS PROGENITOR CELLS. Issue 1 (April 2015)

49. 136 ROLE OF THE TRANSCRIPTION FACTOR CTCF IN THE PATHOGENESIS OF MYELODYSPLASTIC SYNDROMES. (April 2015)